Open AccessFavipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Author(s) -
David M. Lowe,
Li-An K. Brown,
Kashfia Chowdhury,
Stephanie Davey,
Philip Yee,
Felicia Ikeji,
Amalia Ndoutoumou,
Divya Shah,
Alexander Len,
Abhulya Rai,
Akosua Adom Agyeman,
Anna M. Checkley,
Nicola Longley,
HakimMoulay Dehbi,
Nick Freemantle,
Juanita Pang,
Joseph F. Standing
Publication year - 2022
Publication title -
plos medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.847
H-Index - 228
eISSN - 1549-1676
pISSN - 1549-1277
DOI - 10.1371/journal.pmed.1004120
Subject(s) - lopinavir , favipiravir , ritonavir , placebo , medicine , viral load , lopinavir/ritonavir , virology , covid-19 , virus , disease , alternative medicine , pathology , antiretroviral therapy , infectious disease (medical specialty)